Tripep AB (publ.)—Year-end Report 2005

• The company had no net sales in the period. • Research and development costs for the full year were SEK 10.4 m (SEK 12.2 m), with an additional SEK 14.4 m (14.8) capitalised for the full year 2005. • Tripep’s loss after tax for the full year 2005 was SEK -23.9 m (SEK -25.8 m). • Earnings per share were SEK -1.30 (-1.87) for the full year. • The first dosing group in the clinical phase I/II trial on HIV carriers completed their treatment in November 2005. After evaluation, the independent safety committee approved the two remaining dosing groups starting treatment. Preliminary results are scheduled to be available at the end of the first quarter 2006. • With the authorization of an EGM (Extraordinary General Meeting), the Board consummated a new issue with preferential rights for shareholders, which was heavily over-subscribed, raising SEK 28 m for the company before issue costs. Series F and G warrants were listed on the Stockholm Stock Exchange on 29 August 2005. • Professor Robert C. Gallo was elected to Tripep’s Board at an EGM on 26 January 2006. Professor Yiming Shao simultaneously left the Board and became a member of Tripep’s Scientific Advisory Board. • Tripep is beginning the clinical development of ChronVac-C® for the treatment of chronic hepatitis C viral infections, alongside US corporation InovioTM. For more information, please contact Jan Nilsson, Chief Executive Officer Tel: +46 (0)8 449 84 82, mobile: +46 (0)70 466 31 63 e-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research Tel: +46 (0)8 585 81313, mobile: +46 (0)70 928 0528 e-mail: anders.vahlne@ki.se